Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
NCT07560449Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
01
Overview
A Phase 2 trial of QLS4131 in malignant plasma cell neoplasm, multiple myeloma (MM), plasma cell leukemia (PCL), Amyloid Light Chain Amyloidosis, sponsored by Qilu Pharmaceutical. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
QLS4131
03
Conditions
malignant plasma cell neoplasmmultiple myeloma (MM)plasma cell leukemia (PCL)Amyloid Light Chain Amyloidosis
Beyond the preview
Go deeper on NCT07560449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560449.